NCT06021184 (ADEFES) is a clinical trial in Massive Transfusion, sponsored by Ankara City Hospital Bilkent.

Who is sponsoring NCT06021184?

NCT06021184 is sponsored by Ankara City Hospital Bilkent.

What condition does NCT06021184 study?

NCT06021184 studies Massive Transfusion, Bleeding During/following Surgery.

Is NCT06021184 still recruiting?

NCT06021184 is currently recruiting now. Last updated 12 December 2024.

Last reviewed 2024-12-12 · How we verify

NCT06021184: ADEFES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"ADE Fibrinogen/RBC" Ratio on Mortality and Outcome in Massive Transfusion Patients

Recruiting now Last updated 12 December 2024

What this trial tests

trial in Massive Transfusion in 1,679 participants. Currently enrolling.

Timeline

7 November 2023

Primary endpoint
30 October 2025

30 September 2026

Quick facts

Lead sponsor	Ankara City Hospital Bilkent
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,679
Start date	7 November 2023
Primary completion	30 October 2025
Estimated completion	30 September 2026
Sites	1 location across Turkey (Türkiye)

Conditions studied

Massive Transfusion — all drugs for Massive Transfusion →
Bleeding During/following Surgery — all drugs for Bleeding During/following Surgery →

Sponsor

Ankara City Hospital Bilkent

Who can join

18 and older, any sex, with Massive Transfusion or Bleeding During/following Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study focuses on the transfusion of blood and blood products in cases of major bleeding, including massive transfusion scenarios where repeated doses of packed red blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitate, and fibrinogen concentrate are administered. Each of these blood products contains varying amounts of fibrinogen. Previous research has explored formulas to enhance outcomes by examining transfusion ratios such as FFP/ES, ES/platelet, and FFP/ES/platelet. Building on this, our hypothesis is that increasing the total fibrinogen content provided within a short period of time from the beginning of major bleeding reduces mortality and morbidity. To standardize the fibrinogen amounts from different sources under a single pool, we developed a formula that equalizes the fibrinogen content across these products. Using the below formula, we aim to investigate the impact of the overall ADEF/ES ratio on mortality and functional outcomes in major bleeding. Approximate Dose-Equivalent for Fibrinogen (ADE): 1 gram of fibrinogen = 5 units of cryoprecipitate = 1.5 units of FFP, evaluated as total grams of fibrinogen.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of fibrinogen-to-erythrocyte suspension ratio on mortality and functional outcomes in major perioperative bleeding (Approximate Dose-Equivalent of Fibrinogen-to-Erythrocyte Suspension (ADEFES) study): protocol for a prospective observational study.
Demir ZA, Kavak Akelma F, Akça O, Koltka K, et al · · 2025 · PMID 40962355 · DOI 10.1136/bmjopen-2025-099044

Verify or expand the search:

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

NCT07496788 — Investigation of the Role of Internal Jugular Vein Collapsibility Index in Predicting Spinal Anesthesia-Induced Hypotens · not yet recruiting
NCT07536464 — PEEP Strategies and Mechanical Power in Robotic Surgery · NA · not yet recruiting
NCT07534553 — Mechanical Power Ventilation in RALP · NA · not yet recruiting
NCT07501468 — Ventilation Safety in Beach Chair Shoulder Surgery: SafeLM Versus I-gel · NA · not yet recruiting
NCT07502209 — Suprascapular Nerve PRF in Chronic Shoulder Pain · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06021184 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ankara City Hospital Bilkent
Last refreshed: 12 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06021184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing